- Home
- KOPN vs NMRA Comparison
KOPN vs NMRA Comparison
Compare KOPN & NMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | KOPN | NMRA |
|---|---|---|
| Founded | 1984 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 424.9M | 424.4M |
| IPO Year | 1992 | 2023 |
Fundamental Metrics
Financial Performance| Metric | KOPN | NMRA |
|---|---|---|
| Price | $2.50 | $1.65 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 8 |
| Target Price | $4.25 | ★ $8.00 |
| AVG Volume (30 Days) | ★ 3.2M | 849.2K |
| Earning Date | 11-12-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $45,602,295.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $43.37 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 3.02 | N/A |
| 52 Week Low | $0.71 | $0.61 |
| 52 Week High | $4.16 | $3.25 |
Technical Indicators
Market Signals| Indicator | KOPN | NMRA |
|---|---|---|
| Relative Strength Index (RSI) | 49.48 | 32.99 |
| Support Level | $2.28 | $1.73 |
| Resistance Level | $2.44 | $1.93 |
| Average True Range (ATR) | 0.16 | 0.12 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 38.39 | 13.64 |
Price Performance
Historical ComparisonAbout KOPN Kopin Corporation
Kopin Corp is a provider of high-performance application-specific optical solutions consisting of high-resolution microdisplays and optics, subassemblies, and headsets. It serves soldiers, avionics, armored vehicles training and simulation military applications, and others. Its product portfolio includes Microdisplays, Spatial Light Modulators, Optical Modules, Medical, Training, and Simulation. Geographically, it derives a majority of its revenue from the Americas and also has a presence in Asia-Pacific; Europe, and Other Countries.
About NMRA Neumora Therapeutics Inc.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.